Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion

OncoImmunology

Volumn 4, Issue 10, 2015, Pages

  Chang, Li Yuan ^a   Lin, Yung Chang ^a,b   Chiang, Jy Ming ^a,b   Mahalingam, Jayashri ^a   Su, Shih Huan ^b   Huang, Ching Tai ^a,b   Chen, Wei Ting ^a,b   Huang, Chien Hao ^a   Jeng, Wen Juei ^a   Chen, Yi Cheng ^a,b   Lin, Shi Ming ^a,b   Sheen, I Shyan ^a,b   Lin, Chun Yen ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

colorectal cancer; cyclophosphamide; effector regulatory T cells; hepatocellular carcinoma; TNF ; TNFR2

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HERMES ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 84940706538     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1040215     Document Type: Article

References (42)

1. H.Nishikawa, S.Sakaguchi. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27C:1–7; PMID:24413387; http://dx.doi.org/10.1016/j.coi.2013.12.005
2. S.Sakaguchi, M.Miyara, C.M.Costantino, D.A.Hafler. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490–500; PMID:20559327; http://dx.doi.org/10.1038/nri2785
3. A.Liston, D.H.Gray. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 2014; 14(3):154–65; PMID:24481337; http://dx.doi.org/10.1038/nri3605
4. Y.C.Lin, L.Y.Chang, C.T.Huang, H.M.Peng, A.Dutta, T.C.Chen, C.T.Yeh, C.Y.Lin. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J Immunol 2009; 182:6095–104; PMID:19414761; http://dx.doi.org/10.4049/jimmunol.0803829
5. L.-Y.Chang, Y.-C.Lin, C.-W.Kang, C.-Y.Hsu, Y.-Y.Chu, C.-T.Huang, Y.J.Day, T.C.Chen, C.T.Yeh, C.Y.Lin. The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J Immunol 2012; 189:567–74; PMID:22664873; http://dx.doi.org/10.4049/jimmunol.1200266
6. M.Miyara, Y.Yoshioka, A.Kitoh, T.Shima, K.Wing, A.Niwa, C.Parizot, C.Taflin, T.Heike, D.Valeyre et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899–911; PMID:19464196; http://dx.doi.org/10.1016/j.immuni.2009.03.019
7. Y.C.Lin, J.Mahalingam, J.M.Chiang, P.J.Su, Y.Y.Chu, H.Y.Lai, J.H.Fang, C.T.Huang, C.T.Chiu, C.Y.Lin. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int J Cancer 2013; 132:1341–50; PMID:22907255; http://dx.doi.org/10.1002/ijc.27784
8. Y.Grinberg-Bleyer, D.Saadoun, A.Baeyens, F.Billiard, J.D.Goldstein, S.Gregoire, G.H.Martin, R.Elhage, N.Derian, W.Carpentier et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 2010; 120:4558–68; PMID:21099113; http://dx.doi.org/10.1172/JCI42945
9. J.Baba, S.Watanabe, Y.Saida, T.Tanaka, T.Miyabayashi, J.Koshio, K.Ichikawa, K.Nozaki, T.Koya, K.Deguchi et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 2012; 120:2417–27; PMID:22806892; http://dx.doi.org/10.1182/blood-2012-02-411124
10. X.Chen, M.Baumel, D.N.Mannel, O.M.Howard, J.J.Oppenheim. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 2007; 179:154–61; PMID:17579033; http://dx.doi.org/10.4049/jimmunol.179.1.154
11. Y.Okubo, T.Mera, L.Wang, D.L.Faustman. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep 2013; 3:3153; PMID:24193319; http://dx.doi.org/10.1038/srep03153
12. X.Chen, X.Wu, Q.Zhou, O.M.Howard, M.G.Netea, J.J.Oppenheim. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T cell phenotype in the inflammatory environment. J Immunol 2013; 190:1076–84; PMID:23277487; http://dx.doi.org/10.4049/jimmunol.1202659
13. W.J.Housley, C.O.Adams, F.C.Nichols, L.Puddington, E.G.Lingenheld, L.Zhu, T.V.Rajan, R.B.Clark. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol 2011; 186:6779–87; PMID:21572024; http://dx.doi.org/10.4049/jimmunol.1003868
14. M.Chopra, S.S.Riedel, M.Biehl, S.Krieger, V.von Krosigk, C.A.Bäuerlein, C.Brede, A.L.Jordan Garrote, S.Kraus, V.Schäfer et al. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis 2013; 34:1296–303; PMID:23385062; http://dx.doi.org/10.1093/carcin/bgt038
15. W.Zou. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295–307; PMID:16557261; http://dx.doi.org/10.1038/nri1806
16. W.Chen, W.Jin, N.Hardegen, K.J.Lei, L.Li, N.Marinos, G.McGrady, S.M.Wahl. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875–86; PMID:14676299; http://dx.doi.org/10.1084/jem.20030152
17. V.C.Liu, L.Y.Wong, T.Jang, A.H.Shah, I.Park, X.Yang, Q.Zhang, S.Lonning, B.A.Teicher, C.Lee. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007; 178:2883–92; PMID:17312132; http://dx.doi.org/10.4049/jimmunol.178.5.2883
18. Q.Zhang, F.Cui, L.Fang, J.Hong, B.Zheng, J.Z.Zhang. TNF-alpha impairs differentiation and function of TGF-beta-induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway. J Mol Cell Biol 2013; 5:85–98; PMID:23243069; http://dx.doi.org/10.1093/jmcb/mjs063
19. T.J.Curiel, G.Coukos, L.Zou, X.Alvarez, P.Cheng, P.Mottram, M.Evdemon-Hogan, J.R.Conejo-Garcia, L.Zhang, M.Burow et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942–9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
20. I.Kryczek, R.Liu, G.Wang, K.Wu, X.Shu, W.Szeliga, L.Vatan, E.Finlayson, E.Huang, D.Simeone et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69(9):3995–4000; PMID:19383912; http://dx.doi.org/10.1158/0008-5472.CAN-08-3804
21. M.C.Tan, P.S.Goedegebuure, B.A.Belt, B.Flaherty, N.Sankpal, W.E.Gillanders, T.J.Eberlein, C.S.Hsieh, D.C.Linehan. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182:1746–55; PMID:19155524; http://dx.doi.org/10.4049/jimmunol.182.3.1746
22. A.M.Thornton, E.M.Shevach. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188:287–96; PMID:9670041; http://dx.doi.org/10.1084/jem.188.2.287
23. T.Takahashi, Y.Kuniyasu, M.Toda, N.Sakaguchi, M.Itoh, M.Iwata, J.Shimizu, S.Sakaguchi. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10:1969–80; PMID:9885918; http://dx.doi.org/10.1093/intimm/10.12.1969
24. K.V.Tarbell, S.Yamazaki, K.Olson, P.Toy, R.M.Steinman. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 199:1467–77; PMID:15184500; http://dx.doi.org/10.1084/jem.20040180
25. D.Homann, A.Holz, A.Bot, B.Coon, T.Wolfe, J.Petersen, T.P.Dyrberg, M.J.Grusby, M.G.von Herrath. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 1999; 11:463–72; PMID:10549628; http://dx.doi.org/10.1016/S1074-7613(00)80121-1
26. P.Yu, R.K.Gregg, J.J.Bell, J.S.Ellis, R.Divekar, H.H.Lee, R.Jain, H.Waldner, J.C.Hardaway, M.Collins et al. Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J Immunol 2005; 174:6772–80; PMID:15905518; http://dx.doi.org/10.4049/jimmunol.174.11.6772
27. C.Tanchot, F.Vasseur, C.Pontoux, C.Garcia, A.Sarukhan. Immune regulation by self-reactive T cells is antigen specific. J Immunol 2004; 172:4285–91; PMID:15034042; http://dx.doi.org/10.4049/jimmunol.172.7.4285
28. Q.Tang, J.Y.Adams, A.J.Tooley, M.Bi, B.T.Fife, P.Serra, P.Santamaria, R.M.Locksley, M.F.Krummel, J.A.Bluestone. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7:83–92; PMID:16311599; http://dx.doi.org/10.1038/ni1289
29. D.Anz, W.Mueller, M.Golic, W.G.Kunz, M.Rapp, V.H.Koelzer, J.Ellermeier, J.W.Ellwart, M.Schnurr, C.Bourquin et al. CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int J Cancer 2011; 129:2417–26; PMID:21207371; http://dx.doi.org/10.1002/ijc.25902
30. D.Sugiyama, H.Nishikawa, Y.Maeda, M.Nishioka, A.Tanemura, I.Katayama, S.Ezoe, Y.Kanakura, E.Sato, Y.Fukumori et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci 2013; 110:17945–50; PMID:24127572; http://dx.doi.org/10.1073/pnas.1316796110
31. M.S.Naylor, S.T.Malik, G.W.Stamp, T.Jobling, F.R.Balkwill. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer 1990; 26:1027–30; PMID:2148874; http://dx.doi.org/10.1016/0277-5379(90)90043-S
32. K.A.Charles, H.Kulbe, R.Soper, M.Escorcio-Correia, T.Lawrence, A.Schultheis, P.Chakravarty, R.G.Thompson, G.Kollias, J.F.Smyth et al. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009; 119:3011–23; PMID:19741298; http://dx.doi.org/10.1172/JCI39065
33. F.Balkwill. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9:361–71; PMID:19343034; http://dx.doi.org/10.1038/nrc2628
34. S.Beissert, M.Bergholz, I.Waase, G.Lepsien, A.Schauer, K.Pfizenmaier, M.Krönke. Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci 1989; 86:5064–8; PMID:2662193; http://dx.doi.org/10.1073/pnas.86.13.5064
35. G.Soria, M.Ofri-Shahak, I.Haas, N.Yaal-Hahoshen, L.Leider-Trejo, T.Leibovich-Rivkin, P.Weitzenfeld, T.Meshel, E.Shabtai, M.Gutman et al. Inflammatory mediators in breast cancer: Coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011; 11:130; PMID:21486440; http://dx.doi.org/10.1186/1471-2407-11-130.
36. N.Yoshida, S.Ikemoto, K.Narita, K.Sugimura, S.Wada, R.Yasumoto, T.Kishimoto, T.Nakatani. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 2002; 86:1396–400; PMID:11986770; http://dx.doi.org/10.1038/sj.bjc.6600257
37. G.M.Anderson, M.T.Nakada, M.DeWitte. Tumor necrosis factor-α in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4:314–20; PMID:15251122; http://dx.doi.org/10.1016/j.coph.2004.04.004
38. J.P.Waters, J.S.Pober, J.R.Bradley. Tumour necrosis factor and cancer. J Pathol 2013; 230:241–8; PMID:23460481; http://dx.doi.org/10.1002/path.4188
39. J.A.Woyach, T.S.Lin, M.S.Lucas, N.Heerema, M.E.Moran, C.Cheney, D.M.Lucas, L.Wei, M.A.Caligiuri, J.C.Byrd. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009; 23:912–8; PMID:19225537; http://dx.doi.org/10.1038/leu.2008.385
40. S.Madhusudan, S.R.Muthuramalingam, J.P.Braybrooke, S.Wilner, K.Kaur, C.Han, S.Hoare, F.Balkwill, T.S.Ganesan. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005; 23:5950–9; PMID:16135466; http://dx.doi.org/10.1200/JCO.2005.04.127
41. S.Madhusudan, M.Foster, S.R.Muthuramalingam, J.P.Braybrooke, S.Wilner, K.Kaur, C.Han, S.Hoare, F.Balkwill, D.C.Talbot et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor α inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004; 10:6528–34; PMID:15475440; http://dx.doi.org/10.1158/1078-0432.CCR-04-0730
42. M.L.Harrison, E.Obermueller, N.R.Maisey, S.Hoare, K.Edmonds, N.F.Li, D.Chao, K.Hall, C.Lee, E.Timotheadou et al. Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007; 25:4542–9; PMID:17925549; http://dx.doi.org/10.1200/JCO.2007.11.2136